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Abstract
Twenty five patients with acute liver failure
were measured for hepatic venous pressure
gradient as an index of portal pressure during
the course of a transjugular liver biopsy.
Hepatic venous pressure gradient ranged from
4 to 24.5 mm Hg with a mean of 12.8 (5.3) mm
Hg (normal values <5mm Hg). AU patients but
one had increased portal pressure gradient.
Portal hypertension correlated with the degree
of architectural distortion of the liver, as
suggested by a direct correlation between
hepatic venous pressure gradient and the area
of reticulin collapse, evaluated by means of a
morphometric analysis on Sirius red stained
liver slides (r=0.43, p<005). Hepatic venous
pressure gradient was significantly higher in
patients with ascites (15.1 (5) mm Hg, n=15) or
renal failure (14.4 (5.3) mm Hg, n=16) than in
those without (9.3 (3.4) mm Hg and 10*1 (4) mm
Hg, respectively; p<0.05). Portal hyperten-
sion was associated with systemic vasodilation
and a hyperkinetic circulatory state, with
decreased arterial pressure, and peripheral
resistance and increased cardiac output.
Fulminant hepatic failure is a syndrome
characterised by short term development of signs
of advanced liver failure leading to hepatic
encephalopathy in the absence of previous liver
disease.' Fulminant hepatic failure has a very
high mortality, especially when caused by acute
viral hepatitis, which is the most common cause
of this syndrome.'2 Over half of the patients
exhibit clinical signs associated with portal
hypertension, such as ascites and hepatorenal
syndrome.34 It has been suggested that portal
hypertension could be caused by an increased
hepatic resistance to portal blood flow, as a
consequence of sinusoidal collapse and distor-
tion of liver architecture after extensive liver cell
necrosis.3 5
Transjugular liver biopsy allows histological
and haemodynamic studies to be carried out
during the course of fulminant hepatic failure.6
This allows better characterisation of portal
hypertension and the examination of the
relationship between portal pressure, presence
of ascites and renal failure, and the extent of
histological damage. This study presents our
findings in a series of 25 consecutive patients.
Methods
PATIENTS
The study was carried out in 25 patients with
acute liver failure admitted to the Liver Intensive
Care Unit during a three year period. Fifteen
patients were male and 10 female, with an age
ranging from 14 to 62 years (mean (SD) 34 (15)
years) (Table). The aetiology of liver failure was
assessed by clinical history, and by serologic
markers of hepatitis B, hepatitis delta, and
hepatitis A. The possibility of Wilson's disease
presenting as fulminant hepatic failure was
investigated in all patients by measuring plasma
and urine copper and plasma ceruloplasmin
concentrations.
The diagnosis of acute liver failure was based
on the accepted clinical criteria: development of
Clinical data ofthe 25 patients studied
Patient Age Sex Enc Creat HVPG CO SVR
no (yr) MIF Aetiology FullSub (grade) Ascites (smolll) (mm Hg) (i/minl) (dynls.cm-5) Death
1 40 M D Sub IV Yes 230 20.5 4 1800 Yes
2 16 F D Ful II No 71 8 - - No
3 39 M nAnB Ful III No 177 11 - - Yes
4 27 M nAnB Sub IV Yes 265 22 7-5 938 Yes
5 41 M B Sub IV Yes 972 16 8-9 952 Yes
6 51 M nAnB Sub IV Yes 804 14 - - Yes
7 24 M nAnB Ful IV No 221 6-5 13 369 Yes
8 22 M D Sub IV No 53 12-5 - - No
9 55 F Haloth Sub II Yes 53 12 8-1 829 No
10 62 M A Ful IV Yes 946 7 8-2 829 Yes
11 27 F D Sub IV Yes 354 14 - - Yes
12 22 M B Ful IV No 35 8 - - No
13 52 F nAnB Sub IV No 318 7 6-3 977 Yes
14 51 F nAnB Sub IV Yes 557 24-5 6-4 1375 Yes
15 23 F D Sub IV Yes 97 9 - - Yes
16 62 M B Sub IV Yes 610 18 - - Yes
17 42 F nAnB Sub IV No 132 15 - - Yes
18 21 M D Sub II Yes 97 18 - - No
19 24 F B Ful II No 53 7 5 - - No
20 23 M D Sub IV Yes 919 16-5 6.5 1070 Yes
21 14 F nAnB Sub II Yes 132 12 6-2 1058 No
22 25 M nAnB Sub IV No 857 13 13 363 Yes
23 43 M B Ful IV Yes 185 9 - - Yes
24 21 M D Ful IV Yes 238 15 8-4 971 No
25 26 F B Ful IV No 132 4 5.5 1381 Yes
Ful/Sub: fulminant/subfulminant; Enc: encephalopathy; Creat: creatinine; HVPG: hepatic venous pressure gradient; CO cardiac
output; SVR: systemic vascular resistance; M/F: male/female; D: virus delta hepatitis; nAnB: virus non-A non-B hepatitis; B: virus B
hepatitis; Haloth: halothane hepatitis; A: virus A hepatitis.
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hepatic encephalopathy and fall in prothrombin
index below 40% within eight weeks of the onset
of symptoms in the absence of previous liver
disease.' Patients were divided in two groups:
(i) fulminant hepatic failure, when hepatic
encephalopathy appeared in less than two weeks
after the onset of jaundice, and (ii) subfulminant
hepatic failure if hepatic encephalopathy compli-
cated liver failure two to eight weeks after the
onset of jaundice.'
After admission, the patients were transferred
to the Liver Intensive Care Unit. Physical exami-
nation including the presence or development of
ascites and evaluation of neurological status were
performed at least every four hours. All patients
had continuous moniforing of arterial pressure
and urine output. Biochemical analysis includ-
ing standard liver and renal function tests, as
performed daily until death or recovery. Renal
failure was considered to be present when plasma
creatinine increased above 132 [imol/l.
Within 48 hours of admission, all patients
underwent a haemodynamic study during trans-
jugular liver biopsy. Briefly, under local anaes-
thesia a venous introducer (USCI International
Inc, Mass, USA) was placed in the right internal
jugular vein by the Seldinger technique, and the
main right hepatic vein was catheterised under
fluoroscopy using a 7F balloon tipped catheter
(Medi-Tech, Cooper Scientific Corp, Water-
town, MA, USA); repeated measurements of
wedged and free hepatic venous pressures were
obtained by inflating and releasing the balloon.
Portal pressure was estimated from the hepatic
venous pressure gradient - that is, the difference
between wedged hepatic venous pressure and
free hepatic venous pressure.7 In 13 of these
patients a Swan-Ganz catheter was inserted into
the pulmonary artery for measurements of
cardiopulmonary pressures and cardiac output
(Edwards Laboratory, Los Angeles, CA, USA)
(thermal dilution). Arterial pressure was
monitored by sphygmomanometry (Dinamap,
Critikon, Tampa, Florida, USA) and heart rate
recorded by continuous electrocardiograph
monitoring. Systemic vascular resistance (dyn/
sec.cm- 5) was calculated as (MAP-RAP)*80/
CO, in which MAP is the mean arterial pressure,
RAP is the right atrial pressure, and CO the
cardiac output. All measurements were per-
formed by triplicate and permanent tracings
were obtained on a multichannel recorder
(Hewlett Packard 7754B). After that, an 8 F
catheter was introduced in the hepatic vein and a
preshaped liver biopsy needle (Ingenor Medical,
Paris, France) was slipped into the catheter and
the transjugular liver biopsy was obtained in
each patient using the standard technique.6
There were no complications from these pro-
cedures.
Liver biopsy specimens were sectioned
serially and stained with haematoxylin and eosin,
Masson's trichrome stain, and reticulin stain for
conventional histological analysis. In addition,
all specimens were stained with Sirius red F3BA
in order to do a quantitative morphometric
analysis of the reticulin collapse by means of an
automatic image quantifier (Ramtek-935 1), as
previously described.89 The measurements were
based on the contrast between dark (collapse)
and light areas. Three consecutive liver areas
were evaluated for each specimen by one of
us, under blind conditions. The results were
expressed as the mean percentage of Sirius red
stained area of the section. The intra assay
variability of the measurement was of 6%.
STATISTICAL ANALYSIS
All values are reported as mean (SD). The
Student's t test, the X' test and the coeficient of
correlation were used in the statistical analysis of
the results. Statistical significance was estab-
lished at p<0 05.
Results
The mean time between the onset of clinical
symptoms and the haemodynamic study was 21
days, with a range of six to 56 days. The course of
liver failure was subfulminant in 16 patients
(64%) and fulminant in the remaining nine
patients.
The aetiology of acute liver failure was viral
hepatitis in all but one patients. Six patients
had acute hepatitis B (24%), eight acute delta
infection (32%), one had hepatitis A (4%), one
had halothane hepatitis and the remaining nine
cases were considered as non-A-non-B hepatitis
(36%) (Table). Ascites was detected in 15
patients (60%). The ascites had a low protein
content (14 (6) g/l). Renal failure developed in 16
(64%).
As shown in the Table, hepatic venous pressure
gradient ranged from 4 to 24-5 mm Hg with
a mean of 12-8 (5.3) mm Hg (normal values
<5 mm Hg) (Fig 1). All patients but one had an
increased hepatic venous pressure gradient.
Fifteen patients (60%) had a hepatic venous
pressure gradient equal or greater than 12 mm
Hg, and were considered to have severe portal
hypertension, while nine patients had minor
degrees of portal hypertension (hepatic venous
pressure gradient from 6 to 1 1 mm Hg). The 13
patients who had measurements of cardiac out-
put, showed a hyperdynamic circulation mani-
fested by a high cardiac output (7-8 (2.6) 1/min),
and decreased mean arterial pressure (89 (16)
mm Hg) and systemic vascular resistance (993
(387) dyn/sec.cm - 5).
Presence of ascites was related to the severity
of portal hypertension. The hepatic venous
pressure gradient was significantly higher in
patients with ascites (15.1 (5) mm Hg) than in
those without (9.3 (3.4) mm Hg), (p<001).
Moreover, among the 15 patients with ascites, 12
(80%) had severe portal hypertension. On the
contrary, only three of the 10 patients without
ascites had an hepatic venous pressure gradient
above 12 mm Hg (p<0 02).
Patients with renal failure had a higher hepatic
venous pressure gradient than those without it
(14-4 (5.3) mm Hg v 10-1 (4) mm Hg, respect-
ively; p<0-05). Renal failure was present in 11 of
the 15 patients with an hepatic venous pressure
gradient above 12 mm Hg.
The hepatic venous pressure gradient was
significantly higher in patients with subfulmi-
nant hepatic failure (15-3 (4.6) mm Hg) than in
those with fulminant hepatic failure (8.4 (3 1)
966
 group.bmj.com on April 1, 2011 - Published by gut.bmj.comDownloaded from 
Portal hypertension in acute liverfailure
I.-
Figure 1: Individual values of the hepatic venous pressure
gradient (HVPG) in patients with acute liverfailure. The
horizontal line indicates the mean value ofthe whole series.
Patients with fulminant liverfailure are represented by
squares, while those with subfulminant (over two weeks
course) are represented by circles. Note that the latter had a
greaterHVPG than theformer (15 3 (4.6) v 8-4 (3 1) mm
Hg, respectively). The shadowed area represent the normal
range.
mm Hg, p<0 001). Among the 16 patients with
subfulminant hepatic failure, all but two (87.5%)
had an hepatic venous pressure gradient above
12 mm Hg. This was only seen in one of the
nine patients with fulminant hepatic failure
(p<0 001) (Table). Ascites was more common in
patients with subfulminant hepatic failure than
in patients with fulminant hepatic failure (12/16
v three of nine patients, respectively, p=0.08).
Reticulin collapse, measured by the percent-
age of the total area of the section stained by
Sirius red averaged 15-7 (8.4)% (mean value in
normal liver 3-1 (0-5%).9 There was a direct
correlation between the degree of reticulin
collapse and the hepatic venous pressure
gradient (r=043, p<005) (Fig 2).
There were no significant differences in the
degree of collapse between patients with fulmi-
nant and subfulminant hepatic failure (14.6 (90)
v 16-2 (8.3)%, NS).
The whole mortality rate of the present series
was 68%. There were no significant differences
in hepatic venous pressure gradient between
patients who survived and those who did not
(11-6 (3.7) v 13.3 (5.9)mm Hg, NS). The area of
reticulin collapse, however, was significantly
lower in survivors (9.7 (4.7) v 18-1 (8.3)%,
p<002).
Figure 2: Correlation
between the area of reticulin
collapse (as the percentage of
the total area ofthe biopsy
slide stained by Sirius red)
and the hepatic venous
pressure gradient (HVPG).
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Discussion
Portal hypertension usually complicates the
evolution of chronic liver diseases.`' Ascites and
gastrointestinal bleeding caused by ruptured
oesophageal varices are frequent consequences
of severe portal hypertension." It has been
shown that the development of ascites is also
common in acute liver failure,34 and has been
related to the presence of severe portal hyperten-
sion.3 5 Previous studies from our unit, however,
have shown that ascites may occur in patients
with acute viral hepatitis in the absence of portal
hypertension. 12 These patients exhibited an
'exudative' ascites with a high protein and
lymphocyte content and had a good prognosis. 12
The present study further shows that portal
hypertension is common in acute liver failure. In
fact, all but one of the patients studied had a
hepatic venous pressure gradient above the
normal values, thus indicating intrahepatic
sinusoidal portal hypertension.'° Although portal
pressure is determined by the interrelationship
of blood flow and vascular resistance, it is
generally accepted that portal hypertension is
initiated by an increased resistance to portal
blood flow.' '°1 The site of increased resistance in
patients with acute liver failure has not been
clearly established. There is no evidence of
sinusoidal fibrosis and nodular regeneration. '
Similarly, there is no massive infiltration of the
liver, as happens in portal hypertension that may
be associated with haematologic disorders or
amyloidosis,'5 nor evidence of obstruction at the
hepatic outflow, as observed in venoocclusive
disease.'6 Therefore, the most likely explanation
for the increased hepatic venous pressure
gradient is the extensive necrosis and subsequent
reticulin collapse, that probably causes a severe
distortion of the hepatic microcirculation. The
direct correlation found in the present study
between the degree of reticulin collapse and the
hepatic venous pressure gradient, which is very
similar to that obtained by Valla et al5 in patients
with acute viral hepatitis, further supports this
hypothesis. The correlation between the area of
reticulin collapse, however, and hepatic venous
pressure gradient, although statistically signifi-
cant, was poor. This may indicate that other
factors also play an important role in increasing
hepatic venous pressure gradient in acute liver
failure. In addition, it is likely that morpho-
metric analysis in the transjugular biopsies is
subject to some degree of sampling error, which
may obscure this relationship. Measurements of
hepatic venous pressure gradient with the
balloon occlusion technique, however, estimate
the sinusoidal perfusion pressure in a relatively
large area of the liver.`' It is therefore possible
that measurements of hepatic venous pressure
gradient provide a better estimate of the degree
of architectural distortion in acute liver failure
than morphometric analysis of liver biopsies.
Nevertheless, the current finding of a statistic-
ally significant greater degree of reticulin
collapse in patients who died than in the
survivors clearly points out the important prog-
nostic connotation of the severity of histological
damage in patients with acute liver failure. 8
The present study also shows a high preval-
ence of ascites in patients with acute liver failure.
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Our data and previous studies35 indicate that the
presence of ascites is related to the magnitude of
the increase in portal pressure. This would
suggest that, as in cirrhosis,'9 portal hyperten-
sion plays an important role in the pathogenesis
of ascites in acute liver failure.
It is important to note that patients with acute
liver failure showed a hyperdynamic circulation,
evidenced by a high cardiac output and decreased
systemic vascular resistances and mean arterial
pressure. This vasodilatation is thought to be the
mechanism triggering the activation of neuro-
humoral factors contributing to sodium reten-
tion, extracellular fluid volume expansion and
ascites formation.'9 In addition, splanchnic vaso-
dilation, which results in increased portal inflow,
may contribute to increase portal pressure,
specially when the hepatic vascular resistance is
increased.'0 The pathogenesis of systemic vaso-
dilation remains largely conjectural. As sug-
gested in patients with cirrhosis, it is likely to be
of multifactorial origin.'0 '9 A possible explana-
tion is the accumulation of vasoactive substances
of splanchnic origin in the systemic circulation
that are either metabolised by the normal liver
or abnormally released during acute liver
failure.'0202' In that regard it has been reported
that increased levels of substance P are observed
in patients with advanced liver failure and that
these correlate with the degree of hypotension.22
In addition, other factors such as endotoxaemia,
sepsis, and fever may contribute to further
exaggerate these circulatory abnormalities.2'
Renal failure was common in the present series
of patients with acute liver failure. Some of these
patients had acute tubular necrosis, which may
be related to shock, bacteraemia hypovolaemia
and drug nephrotoxicity. Some patients, how-
ever, exhibited 'functional' renal failure, with
many similarities observed in cirrhosis. As in this
condition,23 functional renal failure in acute liver
failure has been related to an imbalance between
neurohumoral factors with renal vasoconstric-
tive activity and renal vasodilators.24 In this
regard, increased plasma renin activity and
decreased renal prostaglandin production have
been reported in patients with acute liver
failure.24 As already mentioned, activation of
neurohumoral vasoactive factors is triggered by
the extreme vasodilation frequently seen in these
patients.'9 Therefore, as in cirrhotics with
hepatorenal syndrome, patients with acute liver
and renal failure exhibit renal vasoconstriction in
the context of marked systemic vasodilation.
This indicates that there should be some areas
where vasodilation is greater than others.
Experimental data suggest that vasodilation pre-
dominates in the splanchnic territory.25 It is thus
possible that if the splanchnic vasodilation could
be overcome, there could be an amelioration in
the systemic and renal circulation.26 This
actually has been reported in patients with
cirrhosis,27 Although there has no t been a
clinical or experimental study exploring this
possibility in acute liver failure.
Finally, it should be emphasised that we had
no complications in obtaining transjugular biop-
sies in patients with acute liver failure despite the
severe coagulopathy inherent to this condition,
even though these studies were frequently
carried out in comatosed patients. Our findings
indicate that the combined histological haemo-
dynamic evaluation provided by this procedure
may help to optimise the medical management of
these critically ill patients.
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